Ionis Q4 rev $227M, FY rev $705M; 2025 guidance rev >$600M, non-GAAP op loss <$495M

IONIS PHARMACEUTICALS INC

2024-FY EPS reported -$3.04 revenue$226,577,000

FY2024 total revenue $705M exceeded guidance; operating loss $475M GAAP, $345M non-GAAP.
WAINUA launched Jan 2024: $85M product sales, $20M royalties; 84% QoQ growth in Q4.
TRYNGOLZA approved Dec 19, 2024 for FCS; first independent launch underway.
Donidalorsen PDUFA date Aug 21, 2025 for HAE; OLE data shows 96% sustained mean attack rate reduction.
2025 guidance: revenue >$600M, non-GAAP op loss <$495M, cash ~$1.7B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.